Log in
Log in
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915


Real-time Estimate Cboe Europe  -  10:59 2022-10-05 am EDT
792.90 DKK   +0.90%
10/04NOVO NORDISK : Goldman Sachs remains its Buy rating
10/04Novo Nordisk - Once-weekly insulin icodec demonstrates superior reduction in HbA1c in combination with a dosing guide app versus once-daily basal insulin in people with type 2 diabetes in ONWARDS 5 phase 3a trial
10/03Novo Nordisk's Once-weekly Insulin Shows Better Results At Lowering Sugar Levels Than Daily Shot
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novo Nordisk A/S : to acquire Emisphere Technologies and obtain ownership of the Eligen SNAC oral delivery technology

11/09/2020 | 09:25am EDT

Denmark - Novo Nordisk A/S today announced that the company has entered into a definitive agreement to acquire Emisphere Technologies Inc. (Emisphere), a drug delivery company with proprietary technologies, such as the Eligen SNAC technology, that enable oral formulations of therapeutics.

Novo Nordisk and Emisphere have collaborated since 2007 and Emisphere's proprietary drug delivery technology Eligen SNAC is used by Novo Nordisk under an existing licence agreement in the oral formulation of Novo Nordisk's GLP-1 receptor agonist semaglutide, which is marketed and sold under the brand name Rybelsus.

Under the terms of the agreement, Novo Nordisk will acquire all outstanding shares of Emisphere for USD 1.350 billion. As part of the transaction, Novo Nordisk will also acquire related Eligen SNAC royalty stream obligations owed to MHR Fund Management LLC (MHR), the largest shareholder of Emisphere, for USD 450 million. Consequently, the total acquisition price is USD 1.8 billion.

With these acquisitions, Novo Nordisk eliminates its future royalty obligations to Emisphere and MHR and obtains full access to the Eligen SNAC technology platform thereby enabling Novo Nordisk to expand the portfolio of oral biologic pipeline assets across therapy areas.

The transaction will be debt financed and will not impact Novo Nordisk's previously communicated operating profit outlook for 2020 or the ongoing share buyback programme. The acquisition is expected to have a net negative impact on operating profit of less than one percent in 2021 and broadly neutral to positive impact in the following years.

The acquisition of Emisphere provides Novo Nordisk full ownership of the Eligen SNAC technology, which has been successfully used under a licence agreement to develop the first oral biologic, Rybelsus' said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk. 'We intend to apply and further develop the technology and use it on current and future pipeline assets with the aim of making more biologic medicines orally available for patients'.

The transaction is subject to customary closing conditions, including approval by Emisphere shareholders and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. MHR and certain other shareholders of Emisphere, collectively owning a majority of the Emisphere shares, have agreed to vote their shares in favour of the transaction.

Novo Nordisk is represented by Davis Polk & Wardwell LLP as legal advisor and Evercore as financial advisor.

About Eligen SNAC Carrier Technology

Eligen SNAC technology enables drug therapies to be provided in a tablet formulation with an absorption-enhancing excipient. Emisphere created Eligen SNAC technology, its proprietary oral drug delivery platform, to facilitate the absorption of small and large molecules without altering their chemical form, biological integrity or pharmacological properties. Notably, the technology enables the transport of therapeutic molecules including large peptides and proteins across biological membranes such as those of the gastrointestinal tract.

About Emisphere

Emisphere is a drug delivery company that utilises its proprietary technologies to develop new oral formulations of therapeutic agents.

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries.


Mette Kruse Danielsen

Tel: +45 30 79 38 83

Email: mkd@novonordisk.com

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
NOVO NORDISK A/S 0.90% 792.9 Delayed Quote.6.91%
All news about NOVO NORDISK A/S
10/04NOVO NORDISK : Goldman Sachs remains its Buy rating
10/04Novo Nordisk - Once-weekly insulin icodec demonstrates superior reduction in HbA1c in c..
10/03Novo Nordisk's Once-weekly Insulin Shows Better Results At Lowering Sugar Levels Than D..
10/03NOVO NORDISK : Gets a Buy rating from JP Morgan
10/03NOVO NORDISK : Barclays reaffirms its Buy rating
10/03Novo Nordisk A/S – Share repurchase programme
10/03Once-weekly insulin icodec demonstrates superior reduction in HbA1c in combination with..
10/03Novo Nordisk Announces Headline Results from the ONWARDS 5 Phase 3A Trial with Once-Wee..
10/03NOVO NORDISK A/S : Share buyback
09/29European ADRs Move Lower in Thursday Trading
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Sales 2022 172 B 22 835 M 22 835 M
Net income 2022 54 653 M 7 239 M 7 239 M
Net cash 2022 2 019 M 267 M 267 M
P/E ratio 2022 32,3x
Yield 2022 1,49%
Capitalization 1 794 B 238 B 238 B
EV / Sales 2022 10,4x
EV / Sales 2023 9,04x
Nbr of Employees 50 816
Free-Float 75,0%
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 785,80 DKK
Average target price 846,28 DKK
Spread / Average Target 7,70%
EPS Revisions
Managers and Directors
Lars Fruergaard Jørgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Stephen Gough Global Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S6.91%238 512
JOHNSON & JOHNSON-3.19%435 445
ROCHE HOLDING AG-12.23%279 092
ABBVIE INC.4.87%251 052
PFIZER, INC.-24.71%249 525